9M 2023 Financial Overview

9M 2023: APPENDIX Sabril 250 200 42 Sabril revenue (Quarterly DKKm) 600 -41% reported 400 150 100 50 200 Sabril vigabatrin 500 mg tablet 500 mg powder for oral solution Sabril revenue (9M - DKKm) -34% reported 0 0 Q3.21 Q3.21 Q3.22 Q3.23 9M 2020 9M 2021 9M 2022 9M 2023 United States Unless otherwise stated, growth rates are at CER. Sabril was approved by the FDA in August 2009. LoE: April 26, 2017. Lundbeck has only promoted Sabril in the U.S. Comments • Down 34% (-34% reported) to DKK 0.3bn in 9M 2023 • Down 38% (-41% reported) to DKK 0.1bn in Q3 2023 Sales impacted by generic erosion from Q3 2017

View entire presentation